<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40280230</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9653</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Osteoarthritis and cartilage</Title><ISOAbbreviation>Osteoarthritis Cartilage</ISOAbbreviation></Journal><ArticleTitle>Intra-articular MM-II for the treatment of knee osteoarthritis pain: Efficacy and safety results from a 26-week, phase 2b, placebo-controlled, double-blind, randomized dose-ranging trial.</ArticleTitle><Pagination><StartPage>897</StartPage><EndPage>906</EndPage><MedlinePgn>897-906</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.joca.2025.04.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1063-4584(25)00975-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Determine optimal dose, efficacy, and safety of MM-II, a suspension of large empty liposomes, for knee osteoarthritis (OA) pain.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A double-blind phase 2b study (NCT04506463) randomized participants 3:3:3:1:3:1 to one intra-articular injection of 1, 3, or 6&#xa0;mL MM-II or 1, 3, or 6&#xa0;mL placebo, respectively. Inclusion criteria included age &#x2265;40 years and radiographic and symptomatic knee OA. The primary endpoint was change from baseline in Western Ontario and McMaster Universities OA Index (WOMAC) pain (range, 0-4) 12 weeks post-injection (multiplicity-adjusted). Secondary endpoints included weekly average of daily knee pain (WADP), WOMAC pain at other visits, WOMAC function, patient global assessment (PtGA), and rescue medication use. Safety was assessed by treatment-emergent adverse events (TEAEs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 396 participants received treatment. In the 3&#xa0;mL MM-II vs placebo group, WOMAC pain numerically improved at week 12 (least squares mean difference [95% confidence interval], -0.24 [-0.48, 0.00]; unadjusted P =&#xa0;0.047; multiplicity-adjusted P =&#xa0;0.085 [primary endpoint not met]). In the same 3&#xa0;mL group, WADP showed improvements at week 12 (-10.9 [-18.9, -2.8]) lasting through week 26 (-11.8 [-20.4, -3.3]; unadjusted P &lt;0.01 at both time points). Numeric improvements were also seen in WOMAC function from week 8-26, and PtGA at weeks 16 and 26. Rescue medication use with 3&#xa0;mL MM-II was consistent with reduced pain. Results were numerically superior with 3&#xa0;mL MM-II vs 1&#xa0;mL MM-II; 6&#xa0;mL MM-II was the least efficacious dose. MM-II was well&#xa0;tolerated, with low TEAE incidence.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MM-II was safe, and the optimal effective dose for the treatment of knee OA pain was 3&#xa0;mL.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schnitzer</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: tjs@northwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Henri Mondor Hospital, University Paris XII UPEC,&#xa0;Cr&#xe9;teil, France. Electronic address: xavier.chevalier@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovsing</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sanos Clinic, Gandrup, Denmark. Electronic address: hel@sanosclinic.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Edith</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hong Kong Center for Clinical Research, Hong Kong, Hong Kong. Electronic address: edith.lau@hkccr.co.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boll</LastName><ForeName>Sidsel L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Sanos Clinic, Vejle, Denmark. Electronic address: sib@sanosclinic.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brahmachari</LastName><ForeName>Ballari</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sun Pharmaceutical Industries Limited, Mumbai, India. Electronic address: Ballari.Brahmachari@sunpharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Sun Pharma Inc, USA, Princeton, NJ, USA. Electronic address: Richard.Chou@sunpharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Tarini</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sun Pharmaceutical Industries Limited, Mumbai, India. Electronic address: Tarini.Joshi@sunpharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wechsler</LastName><ForeName>Roni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Moebius Medical, Tel Aviv, Israel. Electronic address: wechsler@moebiusmedical.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Siu-Long</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Sun Pharma Advanced Research Company Limited, Princeton, NJ, USA. Electronic address: SiuLong.Yao@sunpharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Sveta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sun Pharma Advanced Research Company Limited, Princeton, NJ, USA. Electronic address: Sveta.Weiner@sunpharma.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothekar</LastName><ForeName>Mudgal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sun Pharma Advanced Research Company Limited, Mumbai, India. Electronic address: Mudgal.Kothekar@sparcmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bihlet</LastName><ForeName>Asger R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>NBCD, Herlev, Denmark. Electronic address: abi@nbcd.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conaghan</LastName><ForeName>Philip G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds, UK. Electronic address: P.Conaghan@leeds.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Osteoarthritis Cartilage</MedlineTA><NlmUniqueID>9305697</NlmUniqueID><ISSNLinking>1063-4584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020370" MajorTopicYN="Y">Osteoarthritis, Knee</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007270" MajorTopicYN="N">Injections, Intra-Articular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018771" MajorTopicYN="Y">Arthralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Knee</Keyword><Keyword MajorTopicYN="N">Liposome</Keyword><Keyword MajorTopicYN="N">MM-II</Keyword><Keyword MajorTopicYN="N">Osteoarthritis</Keyword><Keyword MajorTopicYN="N">Pain</Keyword><Keyword MajorTopicYN="N">Phase 2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>8</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>26</Day><Hour>16</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>19</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40280230</ArticleId><ArticleId IdType="doi">10.1016/j.joca.2025.04.006</ArticleId><ArticleId IdType="pii">S1063-4584(25)00975-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>